Learning Objectives

• To discuss current recommendations and outcomes in APL therapy, the management of toxicities such as coagulopathy and the role of new treatment options

• To discuss the management of high-risk APL patients, elderly patients and those with comorbidities

• To share treatment algorithm as a strategy to optimize early diagnosis and to reduce early death in APL patients and to discuss its implementation in community hospitals

This event is approved for up to 1 credit by the Office for Continuing Professional Development. The Office for CPD, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Education (CACME). This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.amaassn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information, please visit our website at: http://wwwmedicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp

This program has received an educational grant from:
Amena, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Gilead, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche